Phase 3 N=43 Efficacy Study of Adalimumab to Treat Interstitial Cystitis
Interstitial Cystitis
Primary: O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score — 27.7; 27.8; 19.6; 19.9 units on a scale — p=0.75
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action
Interstitial Cystitis
Primary: Symptom Improvement of Interstitial Cystitis — 9 Participants
Phase 4 N=20 Botox as a Treatment for Interstitial Cystitis in Women
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Chronic Prostatitis Symptom Index (CPSI-F) — 29.6; 35.2 Total CPSI-F
Phase 2 N=8 Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis
Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 0; 1; 1; 0 number of participants
Phase 3 N=588 Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: 5-Year Freedom From Progression Rate — 85.5; 83.1 percentage of participants — p=0.21
N/A N=78 Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Chronic Interstitial Cystitis · Bladder Pain Syndrome · Cystitis, Interstitial
Primary: Change in the Genitourinary Pain Index (GUPI) 2 Months — 6.6; 4.8 score on a scale
N/A N=16 Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial Cystitis · Pelvic Pain
Primary: Change in Symptom Severity at 4 and 8 Weeks Post-Treatment as Measured by the Total O'Leary-Sant IC Symptom and Problem Index (ICSI/ICPI) Score — -4; -4 units on a scale
Phase 3 N=271 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)
Bladder Diseases · Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 74; 61; 61; 75 Participants
Phase 1 N=47 Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis/Bladder Pain Syndrome
Primary: Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day — -0.7; -1.6; -0.8; -1.7 score on a scale
N/A N=10 PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Chronic Interstitial Cystitis · Bladder Pain Syndrome
Primary: Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) — 6.70 score on a scale
N/A N=97 Mindfulness and Yoga for Pain With Interstitial Cystitis Evaluation
Interstitial Cystitis
Primary: Number of Participants Designated as "Treatment Responders" Based on Global Response Assessment (GRA) — 31; 10 Participants
N/A N=53 URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Percentage of Responders to Treatment — 25 Participants
Phase 2 N=131 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
Cystitis, Interstitial · Painful Bladder Syndrome
Primary: Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up — -1.2; -1.5 score on a scale — p=0.505
Phase 4 N=27 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
Interstitial Cystitis
Primary: The Primary Outcome Will be Assessing the Measurement of Subjective Patient Pain Using the O'Leary-Sant Symptom and Problem Indexes. — 10.92; 10.85; 9.75; 9.92 units on…
Phase 2 N=59 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
Cystitis, Interstitial · Ulcer
Primary: Change From Baseline in the Daily Average Bladder Pain Numeric Rating Scale (NRS) — -1.6; -2.7; -2.5 score on a scale — p=0.142